JPWO2022178158A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022178158A5 JPWO2022178158A5 JP2023549819A JP2023549819A JPWO2022178158A5 JP WO2022178158 A5 JPWO2022178158 A5 JP WO2022178158A5 JP 2023549819 A JP2023549819 A JP 2023549819A JP 2023549819 A JP2023549819 A JP 2023549819A JP WO2022178158 A5 JPWO2022178158 A5 JP WO2022178158A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutical composition
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150832P | 2021-02-18 | 2021-02-18 | |
| US63/150,832 | 2021-02-18 | ||
| US202163180896P | 2021-04-28 | 2021-04-28 | |
| US63/180,896 | 2021-04-28 | ||
| US202163226041P | 2021-07-27 | 2021-07-27 | |
| US63/226,041 | 2021-07-27 | ||
| US202163285785P | 2021-12-03 | 2021-12-03 | |
| US63/285,785 | 2021-12-03 | ||
| PCT/US2022/016840 WO2022178158A1 (en) | 2021-02-18 | 2022-02-17 | Anti-tl1a antibody compositions and methods of treatment in the lung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024508762A JP2024508762A (ja) | 2024-02-28 |
| JP2024508762A5 JP2024508762A5 (https=) | 2025-02-26 |
| JPWO2022178158A5 true JPWO2022178158A5 (https=) | 2025-02-26 |
Family
ID=82931034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549819A Pending JP2024508762A (ja) | 2021-02-18 | 2022-02-17 | 抗ｔｌ１ａ抗体組成物及び肺における治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240336691A1 (https=) |
| EP (1) | EP4294443A4 (https=) |
| JP (1) | JP2024508762A (https=) |
| KR (1) | KR20230158494A (https=) |
| AU (1) | AU2022221712A1 (https=) |
| BR (1) | BR112023016574A2 (https=) |
| CA (1) | CA3207818A1 (https=) |
| MX (1) | MX2023009681A (https=) |
| TW (1) | TW202302640A (https=) |
| WO (1) | WO2022178158A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| JP2022533956A (ja) | 2019-05-14 | 2022-07-27 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａ患者を選択する方法、システム、およびデバイス |
| KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
| EP4665394A2 (en) * | 2023-02-17 | 2025-12-24 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the kidney |
| EP4665395A1 (en) * | 2023-02-17 | 2025-12-24 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the liver |
| AU2024222357A1 (en) * | 2023-02-17 | 2025-08-28 | Cedars-Sinai Medical Center | Anti-tl1a antibody compositions and methods of treating skin |
| WO2024186859A2 (en) * | 2023-03-09 | 2024-09-12 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment for sarcoidosis |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
| US12473370B2 (en) | 2023-10-03 | 2025-11-18 | Absci Corporation | TL1A associated antibody compositions and methods of use |
| TW202545995A (zh) | 2024-01-26 | 2025-12-01 | 大陸商明濟生物製藥(北京)有限公司 | 能夠與ｔｌ１ａ特異性結合之抗體及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080233119A2 (en) * | 2003-08-20 | 2008-09-25 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| WO2009114110A1 (en) * | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| EA201591153A1 (ru) * | 2013-01-02 | 2016-01-29 | Гленмарк Фармасьютикалс С.А. | Антитела, связывающиеся с tl1a, и их применение |
| MX388027B (es) * | 2013-11-13 | 2025-03-19 | Pfizer | Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos. |
| TWI703158B (zh) * | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| MY191324A (en) * | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| US10626180B2 (en) * | 2017-04-20 | 2020-04-21 | Cedars-Sinai Medical Center | Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease |
| JP7332627B2 (ja) * | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ，インク． | 最適化された抗ｔｌ１ａ抗体 |
| JP2022533956A (ja) * | 2019-05-14 | 2022-07-27 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａ患者を選択する方法、システム、およびデバイス |
| KR20220103721A (ko) * | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
-
2022
- 2022-02-17 CA CA3207818A patent/CA3207818A1/en active Pending
- 2022-02-17 AU AU2022221712A patent/AU2022221712A1/en active Pending
- 2022-02-17 TW TW111105899A patent/TW202302640A/zh unknown
- 2022-02-17 EP EP22756948.0A patent/EP4294443A4/en active Pending
- 2022-02-17 JP JP2023549819A patent/JP2024508762A/ja active Pending
- 2022-02-17 KR KR1020237031713A patent/KR20230158494A/ko active Pending
- 2022-02-17 WO PCT/US2022/016840 patent/WO2022178158A1/en not_active Ceased
- 2022-02-17 BR BR112023016574A patent/BR112023016574A2/pt unknown
- 2022-02-17 MX MX2023009681A patent/MX2023009681A/es unknown
- 2022-02-17 US US18/546,947 patent/US20240336691A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018227036B2 (en) | Formulations of monoclonal antibodies | |
| CN110418803B (zh) | 抗rsv单克隆抗体配制品 | |
| JP2020509031A5 (https=) | ||
| JP2020518599A5 (https=) | ||
| JP2024016177A5 (https=) | ||
| JP2021524231A5 (https=) | ||
| HRP20210650T1 (hr) | Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela | |
| WO2007074880A1 (ja) | 抗体含有安定化製剤 | |
| JPWO2022178158A5 (https=) | ||
| JP2025032102A5 (https=) | ||
| US20190010224A1 (en) | Formulations of engineered anti-il-10 antibodies | |
| JPWO2019023564A5 (https=) | ||
| KR20210078514A (ko) | 항-rsv 항체의 제제 및 그의 사용 방법 | |
| JP2020516651A5 (https=) | ||
| WO2025223497A1 (zh) | 一种稳定的抗人IL-4Rα单克隆抗体制剂 | |
| CN113507938A (zh) | 包含抗il-5抗体的药物组合物及其用途 | |
| JPWO2022178159A5 (https=) | ||
| JPWO2019222663A5 (https=) | ||
| WO2018223958A1 (zh) | 一种含c-Met抗体药物偶联物的药物组合物及其用途 | |
| JP7804590B2 (ja) | 抗ｉｌ－３３抗体の処方物 | |
| CA3013443A1 (en) | Parathyroid hormone - anti-rankl antibody fusion compounds | |
| JP2022506042A (ja) | 水性医薬製剤 | |
| JPWO2023081652A5 (https=) | ||
| TW202606715A (zh) | 治療成骨不全之方法 | |
| HK40110950A (zh) | 一种稳定的抗人IL-4Rα单克隆抗体制剂 |